💬In plain words
What the trial is, and whether it could suit you
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB)
* Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion)
* First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17).
* Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial.
* Subjects are willing and able to comply with procedures required in this protocol.
Exclusion Criteria:
* • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17)
* Subjects with legal incapacity
* Subjects who are institutionalized by regulatory or court order
* Subjects who are in dependence to the sponsor or the investigator
University Hospital Cologne
Cologne, Germany
Universitätsklinikum Ulm
Ulm, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky